Takashi Moriyama, Hiromu Aoyama, Shin Ohnishi, Michio Imawari – 1 November 1986 – The effects of supplementation with fibronectin on liver damage and survival in rats with galactosamine‐induced liver failure were studied.
Andrew K. Burroughs, Francois d'Heygere, Neil McIntyre – 1 November 1986
Nicola Tavoloni, Herman R. Wyssbrod, Mary Jane T. Jones – 1 November 1986 – To determine the mechanism and pathway of entry of polar nonelectrolytes into bile, we studied first the permeation of [3H]H2O, [14C]urea, [14C]erythritol, [14C]mannitol, [3H]sucrose, [3H]inulin and [3H]dextran across an isolated, in situ perfused segment of the guinea pig's extrahepatic bile duct. All of these molecules, except [3H]dextran, permeated the bile duct. The diffusive permeability coefficients (cm per sec per 106) ranged from 248 for [3H]H2O to 1.2 for [3H]inulin.
Stuart S. Kaufman, R. Patrick Wood, Byers W. Shaw, Rodney S. Markin, Philip Rosenthal, Bruno Gridelli, Jon A. Vanderhoof – 1 November 1986 – A neurologically normal 3‐year‐old girl with Type I Crigler‐Najjar syndrome was successfully treated with orthotopic liver transplantation. Preoperative serum bilirubin concentrations as high as 31 mg per dl were not diminished with phenobarbital or phototherapy.
George J. Brewer, I. Herbert Scheinberg – 1 September 1986 – After initial promotion of copper excretion with D‐penicillamine, the effect of oral zinc sulphate (3×150 mg/day, loading dose; 3×100 mg/day, maintenance dose) in two children with clinically stable Wilson's disease was evaluated after completion of three years' treatment. The course, judged by clinical, biochemical, and histological parameters was satisfactory in both. The urinary copper concentration reverted to less than 1.26 μmol/24 hours; and the serum copper concentration decreased further during zinc sulphate treatment.
Rolf Hultcrantz, Silwa Mengarelli, Birgitta Strandvik – 1 September 1986 – Liver tissue from five children with cystic fibrosis, obtained through percutaneous liver biopsies, have been investigated via light and electron microscopy. None of the patients had clinical evidence of liver disorder, and their blood chemistry was mainly normal.
Christian Gluud, The Copenhagen Study Group for Liver Diseases – 1 September 1986 – A double‐blind, placebo‐controlled multicenter trial was conducted to determine the efficacy of oral testosterone treatment (200 mg three times daily) in men with alcoholic cirrhosis. By skewed randomization (3:2), 134 patients received testosterone and 87 placebo. Patients were followed from 8 to 62 months (median = 28 months). In the testosterone group, 33 patients died (25%; 95% confidence limits = 18 to 33%) as compared to 18 (21%; 95% confidence limits = 13 to 31%) in the placebo group.